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Abstract
The issues discussed in this article emerged from a study that explored the decision-making processes used by
research participants when deciding to participate in human subjects’ research. We discuss the current research and
regulatory environment and its influences on participant decision-making. The results of this study create a framework
for understanding the challenges of the current informed consent process and offers insights into what may be needed
to create an environment that allows research participants to make more enlightened decisions.
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Introduction
Article focus – The issues discussed in this article emerged from
a 2-year qualitative study that was approved by The University of
Montana Institutional Review Board (IRB) and funded by the National
Science Foundation. In phase 1 of this 2-year study, the investigators
conducted interviews with IRB members from across the country in
order to examine the norms and processes that IRBs use when assessing
and monitoring the adequacy of the informed consent process [1,2] . In
phase 2, the investigators conducted interviews with research subjects
in order to explore their experiences with the informed consent process
and their subsequent decisions about participating in human subject
research. This article, focused on the findings of phase 2, explored
the following three research questions: (1) How do participants make
decisions when invited to participate, including their experiences of
the consent process; (2) what factors influence a decision to enroll in a
study; and (3) what information do participants want when invited to
enroll in studies? This study contributes to a growing understanding
of the decisionmaking processes used by persons who are invited to
participate in research and factors that need attention when developing
regulations that will optimize protection of human subjects.

Background
The US federal regulatory system developed to enhance the ability
of prospective participants to provide their informed and voluntary
consent before participating in research evolved from the work of
the National Commission for the Protection of Human Subjects [3].
This commission was convened in 1973 in response to the growing
challenges posed by the ethics of experimentation; regulatory guidance
for protecting human subjects became codified in the Common Rule
in 1991[4]. The Health Insurance Portability and Accountability
Act (HIPAA) of 1996 added another layer of protection-related
responsibilities [5].
The US federal guidelines stipulate that the consent process for
human subjects research has to provide full disclosure of risks and
benefits, be understandable, take into consideration participant capacity
and competence, and ensure that consent is voluntary [6,7]. Persons
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must be given information in lay language so that they understand and
appreciate the research process and associated risks; consent must be
voluntary and those giving their consent must be legally competent
to do so [8]. Those standards, although seemingly reasonable, have
in practice proven difficult to operationalize. By 1999, Sugarman et
al. had identified more than 377 articles and 3,173 hypotheses when
conducting a literature review that focused on empirical research
studying informed consent and how best to achieve it [9].
In recent years scholars have focused on topics such as participant
comprehension and understanding of the research [10-12], how to
achieve voluntariness [13,14], and policy issues [15,16]. Studies have
shown that participants seem to be particularly vulnerable when
trying to understand the key research concepts of clinical trials. Often
they labor under a therapeutic misconception that leads them to
believe that participating in a medical study would provide access to
better treatments or diagnoses [17,18]. Huntington et al. [19] claim
that although a great deal of thought goes into writing a consent
document, a very small number of potential research subjects read,
or understand it, in any detailed way. Moreover, few subjects seem
to use the informed consent document as a basis for decisions about
participation. Huntington also found that both the readability and the
length of the consent form can impede true consent [19]. Other scholars
assert that research subjects often have an inaccurate or incomplete
understanding of research and tend to overestimate the benefits of
participation. In part this occurs because terms such as risk, harm, and
randomization – terms commonly used in all consent documents –
may not be well understood by those unfamiliar with research [20].
Boiler plate language required to fulfill an institution’s legal obligations
may seem confusing and irrelevant to the prospective participant.
To overcome many of the deficits that participants bring to the
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consent process, investigators have focused on approaches for making
the informed consent process more accessible and understandable.
Researchers have been encouraged to use consent forms that reflect
5th or 8th or 10th grade reading levels. Appelbaum and Grisso
developed a semi-structured interview instrument to assess the
research participants’ competence in making informed decisions
about participating in clinical research; their instrument is designed
to assess skills such as understanding the research and appreciating
the consequences of participating [21]. While the literature base
continues to expand, the identification of approaches that optimize
full disclosure and understanding of the research process remains
elusive. Indeed some scholars have suggested that the unfortunate
consequence of the top-down regulatory approach and the focus on
participant inadequacy seem to have resulted in a system that focuses
on the obligation to document compliance, rather than the obligation
to truly achieve informed consent from prospective subjects [22,23].
New challenges to the informed consent process may be emerging
as clinical research migrates into new environments that engage cadres
of new researchers as well as an expanded population of potential
research participants. In years past, clinical research was primarily
conducted in medical centers or academic medical settings in urban
communities. While some clinical research still occurs in such settings,
it is increasingly conducted in community hospitals, clinics, and private
practice settings, including rural offices where such research engages
rural clinicians and their patients. This migration has increased to the
point where the vast majority of industry-funded clinical research now
occurs in non-academic settings [24-27].
The challenges of conveying complex information in an evolving
research environment underscore the need to better understand how
participants make decisions when invited to join studies, what factors
influence such decisions, and what information the participants want
and need when trying to make informed decisions. Such insights may
bring us closer to understanding what might be needed to better align
the federal guidance with research participants’ needs and expectations.

Research Methods
Sample – Given the exploratory nature of the study a qualitative
research approach was used [28-30]. In order to develop the sample of
subjects who had participated in biomedical or non-biomedical human
subjects’ research, a brief description of the study and invitations to
participate were sent to selected hospitals, centers, institutes, and
research settings across the US. These research sites were selected to
be representative of facilities that serve rural populations. Staff at the
selected sites then disseminated the information about the study to
potential participants who were asked to contact the investigators by
phone or email if willing to participate in interviews. This strategy was
augmented by a snowball approach [31] whereby research participants
contacted others who had been invited to participate in research and
had insights to share. Those willing to participate were then scheduled
for interviews. After conducting 50 interviews no new information was
emerging and so saturation was achieved and the interview process
stopped. This decision is consistent with the standards of qualitative
research methodology [32,33].
The 50 subjects included those who had participated in clinical
trials and other types of research (90%) as well as those who had either
declined or withdrawn (10%) from human subject research. This
resulted in a sample of 33 females (66%) and 17 males (34%) from states
across the US. The sample was comprised of 39 participants (78%) over
the age of 50 and 11 participants (22%) below 50. The higher age of
J Clinic Res Bioeth
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the participants was probably due to the fact that people who are ill
or who have health problems are the ones invited to join or seek out
participation in clinical trials. These categories of people generally fall
in older age cohorts.
The education levels among the participants varied, but were
generally high, with 52% reporting graduate or some graduate
training, 35% some college experience and the remaining 13% a high
school education. The kinds of studies described by the participants
included clinical studies such drugs or devices (72%), psychological,
sociological, longitudinal, or behavioral (46%), and genetic studies
(8%). These numbers exceed 100% because some of the participants
had participated in more than one study and some studies fit more than
one criterion such as a drug study that includes a genetic component.
Data Collection – The interviews were conducted exclusively
by the authors, took place either in person or via telephone, and
lasted from 45 minutes to one hour. The participant interviews were
conducted between July 2009 and July 2010. The design of the semi
structured instrument drew on findings from a pilot study that the
investigators conducted in 2007 with rural research participants as
well as the earlier phase of the investigators’ research that focused
on the decision-making processes used by IRBs when overseeing
research that involves human subjects [34,35]. Using semi-structured
interview protocols allows the exploration of unanticipated issues and
the pursuit of rich examples while adhering to a core set of domains.
The core domains used in the second phase of the project are listed
in Table 1. Consistent with established qualitative research practices,
the interviews continued until data saturation had been achieved, i.e.,
no new data surfaced. The authors transcribed the interviews verbatim
in preparation for qualitative analysis for which Atlas.ti, a qualitative
coding software application, was used. The thematic coding was
conducted by both authors; it evolved as new themes emerged.

Results
A sizeable number of representative quotes are provided to
showcase the findings of how participants experienced the informed
consent process and made decisions about enrollment. The quotes
attest to a remarkable homogeneity, among participants, with respect
to core beliefs and expectations that influenced or bolstered their
decisions.
The consent process – When recounting their experiences with the
consent process the participants generally seemed to view the process
as a standard or routine activity and did not seem to question either
the information or the process itself. Most of the participants (84%)
reported that they had read the informed consent document and that
Experiences with research including invitations to participate
Experience with informed consent forms and procedures
Relationship with the researchers suggesting enrollment
Factors that influence decision to join: illness, compensation, altruism, personal
benefits
Role of funding source, purpose of study, and researcher compensation on
decisionmaking
Perception of voluntarism (ability to decline or withdraw, ‘gentle coercion’?)
Perception of anonymity and confidentiality
Impact of participant vulnerabilities
Impact of perceived risks and benefits
Future willingness to join a research study
Information subjects want and need to make informed decisions
Table 1: Core Domains for Key Informant Interviews.
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they had been given enough time to think about participation before
making a decision. Many reported that they had had to initial every
page of the consent form and that the person overseeing the consent
process underscored the importance of reading and understanding
the nature of the research study. Some were given the form in advance
and most reported that they had been encouraged to ask questions.
Only 3 participants reported that they had felt very rushed during the
consent process and felt that they did not get enough time to process
the information.
But in spite of these efforts to fully inform, the data show that
achieving full understanding of the information provided through the
consent process can present a number of serious challenges for research
participants. These challenges seem apparent even for participants
who, as in this study, are very well educated. As participants appeared
to make the decision to join a study before the full consent process
was finalized, reading and signing the consent form became a social
formality. Consequently, little attention was given to statements about
risks and benefits, who was funding the research, or protection of
anonymity and confidentiality. For example, 78% could not remember
who funded the research study. Most participants thought that the
research provided valuable benefits such as access to state-of-the art
medical tests, or the option of getting the best drug. As one respondent
explained: “Well more for less. Better care and a better cure. My
treatment would be more complete and there would be less chance of
reoccurrence.” (p47)
Factors influencing decisions to participate – The data show
that the participants’ decisions were influenced by a number of
factors including illness status (66%), altruism (42%), and financial
benefit (22%). The potential for personal benefit seemed to play an
important role when deciding to enroll in a study. This seemed true
particularly when there was a definite benefit like obtaining a drug or
device, or some level of monetary compensation. Two thirds of the
participants acknowledged that they had received some compensation
for participating. When asked about such compensation, twenty-eight
percent cited the provision of additional medical tests or medications.
This is exemplified by the respondent who said: “But I got the drug
- I am sure the drugs are expensive. The one pill was $150 each and
I took that twice a day.” (p.40) Twenty-eight percent cited monetary
compensation as a factor in their decision-making. Explained one
participant: “When I found out I would get paid, I made up my mind I
was going to do it.” (p.2) Most of the monetary compensation was quite
modest and involved benefits such as reimbursements for parking,
travel, or time and effort. Noted one participant: “Sure. You got $50
up front and $25 when they drew blood. That was it. That was their get
rich scheme.” (p17)
The decisions to participate were also influenced by the mode of
recruitment. Forty-six percent of the participants reported that their
physician or healthcare provider had suggested they participate, 36%
that they had responded to a newspaper advertisement or a poster,
while 28% said the recommendations had come from friends and
family. Three participants (6%) responded that their participation
was mandatory in order to get credit for required course work. Since
some participants offered more than one mode of recruitment for their
participation in the studies, the numbers do not add up to 100%.
A trusting relationship with a healthcare provider or researcher
seems to influence the decisions a prospective human subject makes.
Participants generally believed that such a person would have the
subject’s best interest at heart. Said one participant whose physician
had suggested participation: “[It was my] doctor who recruited me. I
J Clinic Res Bioeth
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trust him completely and I love the man.” (p.14) others said it was hard
to say no if a trusted clinician or a colleague would ask for participation.
The need to maintain, not disappoint, or not jeopardize a relationship
was strong among the participants. If a participant had responded to
an ad about participating, it seemed as if the decision to participate
was formed more or less at the time of finding out about the study.
Combining intention with opportunity, one participant explained: “I
had seen other ads for other research things. I was just curious and we
were planning to get a flu shot that week. We were going on the cruise
and wanted the protection.” (p18)
The ability to withdraw from a study, an important component
of achieving true voluntariness, seemed at times to pose difficulties.
While most said it would have been easy to withdraw (76%), many also
said that in practice it would feel like “letting the researchers down” or
“like ruining the study” (24%). When asked if it would have been easy
to withdraw from a study, a representative quote was as follows: “Oh
yeah, at any time. But, I would have felt guilty because I know, as a
coordinator you put in a lot of work into the study and into recruiting
people and they pull - and then you can’t use any of the information.”
(p12). Explained another: “It would have been easy in terms of the
researcher. I would personally feel like a failure and that it would come
back to me as karma.”(p35)
Appreciation of risks and benefits – Many participants seemed to
minimize potential risks and overestimate the benefits of participation.
Indeed, eighty-eight percent believed that the benefits of participation
outweighed the risks. They believed that participation would bring
tangible benefits to oneself or to others and that the risks would be
minimal or non-existent. This approach to risk assessment, even in
cases where potentially severe risks were clearly stated in the consent
documents, is exemplified by the following representative statement:
“Because I don’t presume there are any risks. They didn’t really talk
about them. I think that maybe because the form of the medication is
a nasal spray it is less intense than pills or injections. Maybe there are
fewer risks? I might have been more leery about medication in pill form.
Maybe that is naiveté on my part. I guess there is no reason to suspect
a nasal spray is less potent.” (p38) This statement was made by a welleducated person whose consent document clearly stated that the risks
were potentially life threatening. Some participants ignored or refused
to even read about potential risks or side effects. This approach is seen
in the following comments: “But I didn’t read about the side effects in
the informed consent form because I don’t want to slant my thinking.”
(p14) Another participant explained: “I thought it was a formality - like
what you sign before surgery, the form saying you might die. It was just
like the legal language thing and I didn’t take it seriously.” (p4).
Some participants expressed almost blind trust in the system and
believed that if a study is allowed to be conducted and is approved, it
must mean that participating is safe and that the risks are minimal.
In this context the signing of the consent document was seen more
as a formality. Participants offered explanations such as: “I didn’t see
any risks. I do blood draws regularly and that wasn’t scary for me.”
(p32). Said another: “ I knew it [the drug] had come a long way to get
to the point where they are doing trials. So I felt comfortable knowing
there were no real risks, that it was safe.(p12) Another participant
suggested: “I would not be part of a study where someone from out
of town comes in to the [local hotel] and recruits local subjects and is
around for three weeks. It adds legitimacy that it is run locally.” (p18)
Explained another: “I admit to being fairly trusting - a philosophy in
my life. Perhaps not always good but I do what is in front of me. It
was presented in a professional manner in an office setting by a person
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who was articulate.” (p19) Said another “Well the only thing I thought
was - well they do stents all the time. I can’t imagine a stent that would
go wrong and maybe the old ones don’t work well.”(p10). Even a risk
statement that identified the potential risk for a heart attack would not
deter a participant who trusted the doctor who suggested participation:
“Yes. That heart failure was the main risk, but we just felt that it wasn’t
- well like the doctor said, it is treatable and so we continued. And not
knowing the history of the 6 women who got heart failure or what
happened to them. So it is hard for us to know what is the best thing to
do. And I haven’t had a heart problem yet.” (p47)
In addition to trust in the system, some also believed that
participation would provide access to what would become the new
gold standard or the miracle drug. Such was the belief of the person
who had severe diabetes and who had responded extremely well to the
study drug; he was certain that study participants would be the first
to receive prescriptions for the new drug. “I am waiting for the drug
to be released. I will be the first patient in [my state] to sign up.”(p45)
Another participant whose doctor had suggested participation added:
“Well, then I started talking myself into it and he [the doctor] said
the D-drug would be the new Lipitor, the miracle drug. That sounds
so hopeful.” (p14) When holding such beliefs, research participants
appeared to overlook the consequences of the research design such
as randomization, the phase of the clinical trial, and other important
factors. This was exemplified by the respondent who explained: “So I
thought well if it works, I would be right in line and first to get the
full treatment.” (p48) Participants also perceived that the additional
time and more interaction with healthcare would translate into better
treatment and personal benefit such as a cure for their disease. “Well
at that time I did, though, at that time I didn’t see either benefits or
risks. This is how naive I was. I thought maybe if it wasn’t a placebo
maybe it would cure my osteoporosis.” (p16) Participation in a clinical
study does indeed provide the opportunity to get more attention from
a healthcare provider and often entails more tests than what is usually
required. In the case of cancer trials, participation was often perceived
as a last resort and the only way to gain access to treatment.
Given the overall approach to risk appraisal, few participants had
any understanding, or even awareness, of the risks and challenges of
data sharing or management. Persons who participated in genetic
studies or longitudinal studies that required release of personal data,
including DNA, also minimized risks associated with confidentiality
and privacy reporting that they were not particularly concerned about
any associated risk. When asked about the study’s provision of privacy
protection said one participant: “I knew there couldn’t be much
harm.” Another participant in a gene study noticed: “None really. I
always worry about privacy issues but they said it was all identified by
numbers and privacy would be safe.” Regardless of the type of study,
the vast majority of participants (81%) presumed that the protection of
privacy was adequate assuming that activities in a “legitimate” setting
such as a hospital setting or researcher’s office setting would ensure
such protection. Neither the understanding of what privacy protection
should include nor who would have access to any data were well
developed. Said one participant: “It was private. I was the only one. I
was the only one in the room.” (p7) Others explained when asked about
protection of privacy: “Didn’t even consider that.”(p1) “Yes. They seem
to be careful of how they are handling phone calls and the personal
upfront interview.” (p17)
What participants need and want to know – The semi-structured
instrument included questions about what the participants perceived
as important information for decision-making regarding participation
J Clinic Res Bioeth
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in research. Included in the instrument were questions such as: what
are the most important pieces of information, what do you want
to know; what do most people want to know, and were there any
surprises? Generally the respondents wanted understandable and
relevant information regarding what was required of them and what
the “pros and cons” of participating would entail. Said one participant:
“I think the risks and the time involvement. And the benefits. What
do I get? What is the benefit to me personally? What am I going to get
out of this? The results may not help me but maybe I get physicals and
transportation and honorarium.” (p.5)The vast majority also wanted
to make sure that they would not be harmed if they participated in
the research. As one participant explained: “I think they want to make
sure they are going to be safe and it won’t hurt them. They want to
know there is some benefit for them. Some do it for totally altruistic
reasons but most people want to see some benefit to them. Like trying a
new medicine they wouldn’t be able to get otherwise. Like, I never had
anything to treat this condition before and maybe I will get better if I
am on the study. Most people hope they will get better; they hope they
won’t get the placebo.” (p12) Those who participated in clinical trials
wanted to make sure that they would get, at minimum, the standard of
care. Participation then seemed to provide the added benefit of possible
improvements on the current standard of care.
The findings suggest that regardless of background, education
level, or age, participants consistently blurred the distinction between
research and treatment. While affirming the importance of learning
about risks, the participants also believed that they would not be invited
to participate if the risks were other than minimal. Most believed that
research would provide individual benefit and even optimal personal
benefit. Two quotes reflect this orientation; “But I think there is an
assumption that you make in a way - that if someone asks you to do
this, like if a medical persons asks you - you think they already know
the risks are minimal and they would not put you at a great deal of
risk. They have your wellbeing at heart. That is how most people would
think. But it may not be true. They are doctors. There is the trust thing.”
(p21) “I think one wants to understand what the study is about. To
make sure that information is straightforward. There was nothing
about it being double blind, or placebo, or any negative consequences
with being part of either group. I would not have participated if it had
been random assignment to a group with shot and/or placebo.” (p18)
Most participants desired more information about two issues
that generally are not fully explained or disclosed during the consent
process: (1) the commercial purposes of the research and (2) the extent
of researcher or institutional compensation. Regulatory guidelines do
not currently stipulate how much information about either issue needs
to be disclosed during the consent process. Prior to taking part in the
interviews, most participants had not realized that some studies might
be designed for commercial purposes, such as extending a patent or
developing a “me-too” drug, a drug that replicates an already existing
drug. Most of the participants were also unaware of the potential for
researcher compensation. Participants thought it was dishonest not to
be transparent about researcher compensation and the full purpose of
a study and said that hiding such information would not be acceptable.
Most (90%) wanted to know whether a study had such a commercial
purpose and the vast majority (80%) reported that disclosure of such
information could influence their decisions about participating in
research in the future. Said one participant: “They should know; the
person should know the purpose of the study. You have Ambien 12
(hours) and Ambien CR (time release) and so they got the patent
extended with the CR. They are looking at whether a formula makes
a difference - and I think the study participant should be told exactly
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what is going on. It’s coercion otherwise. We are looking at the
formulary tweak. You have to be honest. If your study is not valid or
fair or if you can’t tell the truth, rethink the study. You have to know
the real purpose.” (P25). Said another: “Patents. Sure. Absolutely, for
sure. I absolutely want to know. And I have a pretty high awareness of
that issue and some of the drugs I have to take are still under patent and
the costs are dramatically different from the generic drugs that I take.”
(P28) Among those who said it would not influence their decisions
about participation, they still felt they should be informed about such
issues.
Similarly, most participants (84%) wanted to be fully informed
about researcher compensation. The tacit assumption among
participants seemed to indicate a belief that the conduct of and
participation in research studies included some level of altruism or
mutuality on the part of both the researcher and the participant. One
participant deliberated in this way on that topic: “I would think twice
about a study if there was an enrollment or other [financial] incentive
for the researcher. It would depend on the amount and if they could
use tissue, blood or psychological profile for long term benefit. I would
feel deceived if someone was getting an enrollment or other incentive
and not tell me. It would make a difference who was funding the study.
More information should be provided - a statement like compensation
for research - it is misleading because you think it [what the researcher
is getting] is on par with what is happening to you.”(p8) Another one
said: “Yeah. That is pretty important information. Probably. Especially
if there was a lot of compensation you might think twice about wanting
to join. You would want to know if the doctor is doing it for the money.
I would want to know if he is getting five grand for putting me through
some study.”(p2) The importance of transparency was expressed by
this participant: “I may be less inclined if I thought there was a possible
COI - that whoever was funding it stands to benefit from the findings.
If Pfizer was doing a study to show that their drug is the hottest thing
on the market. I don’t have time for that kind of study. I would not
participate; I would have no time for that. I can understand the benefit
of running trials and trying to involve patients. I would want to know if
my primary physician asked me, I would try to find out: OK could there
be a benefit to my care provider by making me participate or framing
data. And so if I started to feel pressure like someone really encouraging
me, I would say no. I would immediately go into the terrible-two mode.
If you are trying to push me…no thank you, I don’t want it. I have no
time to sort through the potential conflicts.” (p5) “Wow. We didn’t
know that - they get paid for helping to run these studies? Really? Yes.
I would want to know. I didn’t realize they might get paid. Like my
cancer nurse, is she paid by the cancer research foundation or how?
Yes. I think you should know that. They should tell you. Who is getting
paid and who is running the study and the whole reason why they are
doing it. It is a matter of respect.” (p47)
Willingness to join future research – When asked if they would
be willing to participate in future studies 89% said they would join
another study. Of those, 61% said they would join only under certain
conditions. The “yes-but” group offered statements like: “I feel there are
caveats.” (P14); “I would if I could get all of the information beforehand.
Then I could make an informed decision. I could be thinking it over.
I never even realized that doctors do research in their clinics.” (P7);
“Well, it would depend on what the benefit would be and how much
information I would be given. I am not adverse but I would now ask
more questions.“ (P10); and “Yes but with a great deal more curiosity
about the sponsors and the purpose of the study.“ (P19) There were also
a few participants who expressed the view that if they had been put in
the placebo or comparison group they would have withdrawn from the
J Clinic Res Bioeth
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study. Said one mother whose child was participating in a behavioral
study: “[We] will continue only if we are randomized to the telephonecontact therapy (with me, as opposed to face-to-face meetings with [my
child]. The study is a comparison between these two modalities.” (p15)
Although most participants seemed relatively satisfied with their
experiences of participating in research there were some for whom
the experience was less than expected. Indeed all of those who said
they would not participate in another study also reported negative
experiences with their research participation. It appears that if a person
had a less than optimal experience when participating in the research,
it led to an expression of what could have been done better and what
additional information could have been provided. Indicative of this
perspective, one participant said: “I would like to know the results of
other trials; is it totally new or are there some results? And I would like
to know the difference between this stent and others. And I would like
to know the benefits - what are you [the participant] going to get out
of this…[is it] attention and follow-up? I think that is all part of the
disclosure.” (p10) Another commented: “I mean thinking about this
experience - I would have liked to have a better understanding of how I
was going to feel. So even though it didn’t have permanent effects that
I know of - other than bad memory - I would have liked to know what
it was going to be like. I don’t recall having that described. Not to the
degree of what I would experience.” (p4)
Almost all of the participants expressed a desire to receive study
results. Many expressed that some form of closure would have been
appropriate. When asked if there were surprises, many did say that they
were disappointed that they had not been re-contacted and informed
about study results as was promised or anticipated when enrolling. The
participants reported that the lack of such information dampened their
willingness to participate in future studies.

Discussion
The findings from this study suggest that the guides that regulate
the informed consent process – particularly the informed consent
forms - may not be well aligned with the ways in which human subjects
make decisions about participating in research. While claiming to have
read the consent forms, most participants in this study had disregarded
or discounted much of the information contained in them. The
required information about sponsorship/funder, full purpose of the
study, risks, benefits, confidentiality and privacy was marginally
registered if the research seemed “legitimate.” Key information in the
consent forms was also disregarded or underestimated when the reason
for participation was motivated by disease or some other personally
compelling issue such as monetary reimbursement, an opportunity for
the newest treatment or a “good deal” such as getting a flu shot for free.
The participants seemed to make their decisions about participation
based on intervening factors related to where the research is conducted
(legitimacy of the setting), who conducts it (skilled clinician or
colleague), and the relationship with or perceptions of the researcher
(high levels of trust). When the research is offered in a clinic or other
medical setting, participants appear to presume that the doctors or
investigators know a great deal about the research and have considered
all of the risks so that the participants will not be harmed. Thus even
well-educated participants who stated that they read the informed
consent documents for clinical studies seemed to make decisions based
on their expectation of obtaining optimal treatment, the miracle drug,
or the new gold standard. Participants did not fully understand that the
study drugs may never make to it to the market, may be prohibitively
expensive and so inaccessible to most people, or may have very serious
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side effects or consequences. When enrolling in non-clinical studies
participants often reported an obligation to participate so as not to
disappoint, or jeopardize the relationship with the researcher.
Indeed, there was such trust in the system and in the safety of
participation that subjects often perceived that there was a greater
personal risk associated with receiving either a placebo or the currently
approved standard of care. If suspecting that they would be put in the
placebo arm or existing treatment arm, some participants noted that
they might even pull out of a study, a decision that could jeopardize
randomization and so undermine the research integrity. Even those
familiar with other types of research did not seem to transfer that
knowledge when entering the medical realm via a clinical trial. What is
surprising and deserving of attention when designing future policies for
human subjects protection is that these findings consistently emerged
even though this study was conducted with well educated, older people
who would not have been deemed “vulnerable” or “at risk” in terms
of their ability to read consent forms, understand the study, or make
informed decisions.
These findings suggest that current approaches for protecting
human subjects, some of which include requiring that consent forms
contain more information and more detail, are written at ever lower
reading levels, or use checklists or videos to ascertain informed
consent may fail to overcome the beliefs and expectations that the
participants bring to the research enterprise. In part, participants may
be conditioned by western society to expect and ignore all sorts of
cautionary language. There are warnings if you get on a rollercoaster,
visit a ski hill, or walk along a nature path. Televised pharmaceutical
advertisements extol the benefits of the newest drug and then follow
the claim with a long list of potential side effects. When arriving for
a medical appointment, patients are quickly given HIPAA and other
privacy-related forms; in response, with a quick glance, patients often
ask where they are supposed to sign. This disregard of warnings seems
to be carried over to the consent process where the desire to participate
seems to override serious appreciation of risk.
This kind of human behavior can also be understood by the
theory of cognitive dissonance that suggests that individuals tend
to seek consistency among their cognitions (i.e., beliefs, opinions)
[36]. When there is an inconsistency between attitudes or behaviors
(dissonance), something must change to eliminate the dissonance. In
the case of a discrepancy between attitudes and behavior, it is most
likely that the attitude will change to accommodate the behavior. There
are three ways to eliminate dissonance: (1) reduce the importance of
the dissonant beliefs, (2) add more consonant beliefs that outweigh
the dissonant beliefs, or (3) change the dissonant beliefs so that they
are no longer inconsistent [37]. Dissonance occurs most often in
situations where an individual must choose between two incompatible
beliefs: believing on one hand that research participation may have
risks versus believing on the other hand that your clinician would
not have suggested participation if the activity was risky. So in some
respects, the extent to which the participants discounted information
in the consent form, or even the process itself, is not surprising. Thus
it is not more information in simplified language that matters when
inviting participants to join a research study, but conveying the right
information in ways that helps participants better understand how
the goal of research and the goal of clinical care may be different from
one another. Only when participants started thinking about issues
like researcher/institutional compensation and commercial purposes
of research such as obtaining patents or obtaining market shares did
they begin to discern that there might be a difference between the goal
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of a particular research study and the goal of optimal individual care.
Such recognition seemed to lead to a sort of “aaaha moment” whereby
the participants then seemed to view issues such as receiving optimal
personal care or not disappointing their doctor in a different light.
These findings suggest that if we truly want to enroll enlightened
volunteers, we have to find ways to communicate in practical terms
the actual purpose of the study, the results of past studies, what the
investigator knows about the research intervention, and what the
investigator is being paid for helping carry out the research. Any
strategies that would help the participants clarify the differences
between the goals of research and the goals of personal care deserve
further exploration. Our study did not explore how such information
should be provided, or how it could influence enrollment. Thus more
research is certainly warranted. We need to better understand the range
of factors and beliefs that participants bring to their decision making.
We also need to better understand how human subjects will experience
greater transparency about the overall research process.
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